Achyut Healthcare Ltd

Board action

• Board approved unaudited quarterly results for the quarter ended 30 June 2026.
• Company reports Pharmaceuticals as the single reportable segment.
• Results prepared per IND AS and Companies Act regulations.
• Limited Review Report attached.
• Board meeting held on Aug 13, 2026 for results approval.

Meeting Details

• Date: Thursday, 13 August 2026.
• Venue: Registered Office, 504 Iscon Elegance, Nr. Ananddham Jain Derasar, Prahladnagar Cross Road, S.G. Road, Ahmedabad 380015.

Key Agenda Items

• To consider and approve the unaudited financial results for the quarter ended 30 June 2026.
• Any other item with chair and majority director approval.

Other Notes

• Trading window remains closed till 48 hours after declaration of financial results for quarter ended June 30, 2026.

Overview

• Amalgamation of the transferor into the transferee; transferor to dissolve without winding up.

Rationale

• Consolidates related businesses to expand portfolio, capacity, and market reach, enabling efficiency and cost synergies.

Key terms

• Nature: Amalgamation; transferor dissolves; transferee issues equity shares as consideration.
• Share exchange ratio: 119 transferee shares for every 50 transferor shares.
• Record date and effective date not specified; approvals include NCLT sanction and shareholder/creditor approvals.
• Related party: promoters from same group; at arm's length per Share Exchange Report.
• Regulatory steps: NCLT sanction, shareholder/creditor approvals; filing with stock exchange for no-objection letter.
• No cash consideration; equity shares issued by transferee to transferor shareholders.

Financial impact

• No cash; exchange of shares as consideration.
• Pre/post shareholding: Transferor promoters 28.74% pre; 45.80% post; Public 71.26% pre; 54.20% post.
• Post-amalgamation total issued shares for Transferor entity: 62,81,68,660.

Impact on stakeholders

• Shareholders of Transferor receive transferee shares per ratio; Transferor dissolves.

Status & next steps

• Board approved on July 14, 2026.
• Subject to NCLT sanction and required approvals.
• Filing with stock exchange for no-objection letter; record/effective dates to be announced.

Status of dematerialisation/rematerialisation

• RTA confirms dematerialisation/rematerialisation details for the period were furnished to all exchanges.
• Certifications confirm the securities dematerialised/rematerialised have been reported to all listed exchanges.